Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FAP 2: Utility of Gallium-68-Fibroblast Activation Protein Inhibitor (FAPI) PET in Biliary Tract Cancers: A Prospective Study

NCT07337850 is registered in ClinicalTrials.gov with Tata Memorial Centre as lead sponsor.

NCT NCT07337850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FAP 2: Utility of Gallium-68-Fibroblast Activation Protein Inhibitor (FAPI) PET in Biliary Tract Cancers: A Prospective Study
Lead sponsor
Tata Memorial Centre
Phase
Observational
Overall status
Recruiting
Start date
September 25, 2024
Completion date
March 31, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gall bladder cancer, intrahepatic cholangiocarcinoma (icc)